Orphazyme investor relations material

Listen to the latest call from Orphazyme

Orphazyme A/S, a biopharmaceutical company, develops therapies for the treatment of neurodegenerative orphan diseases. The company's lead drug candidate is epoprostenol sodium and its analogues, Phase III ready lipidic compounds, which are being developed as an innovative treatment option targeting the underlying cause of these diseases. The company was incorporated in 2009 and is headquartered in Copenhagen, Denmark.

  • Ticker

  • Country


Dig deeper into the Orphazyme fundamentals on Quartr.